Corporate Profile

Harmony Biosciences is a U.S. commercial-stage pharmaceutical company dedicated to developing and commercializing innovative therapies for people living with rare neurological disorders who have unmet medical needs. Established by founder Paragon Biosciences LLC, our mission is to positively impact the lives of those living with rare diseases who are so often underserved.

In August of 2019, Harmony Biosciences received FDA approval for its first commercial product, WAKIX® (pitolisant) tablets. Harmony is currently evaluating pitolisant for broader applications in neurological disorders that may be mediated by the H3 receptor. See product pipeline for further details.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases



HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024

Apr 16, 2024

PLYMOUTH MEETING, Pa. , April 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2024 financial results on Tuesday, April 30, 2024 , before the open of the U.S. financial markets.

HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST

Apr 11, 2024

TPM-1116 preclinical data suggest a potential best-in-class profile that could transform the treatment of narcolepsy and other sleep/wake disorders Expands Harmony's innovative neuroscience pipeline and strengthens its leadership position in sleep medicine PLYMOUTH MEETING, Pa.

HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME

Apr 03, 2024

Trial initiation a step toward potentially treating excessive daytime sleepiness and behavioral symptoms in patients with PWS PLYMOUTH MEETING, Pa. , April 3, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) has initiated its global Phase 3 registrational trial,

Events

Contact Information

ir@harmonybiosciences.com